{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013642","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.125002+00:00","generated_at":"2026-06-12T04:09:03.206928+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quanterix Q2 revenue $31M (+32% YoY), net loss narrows to $6.1M; raises FY revenue guidance to $110-116M","bullets":["Revenue $31.0M, +32% YoY, including $1.5M one-time product/license benefit; 9% sequential growth.","GAAP gross margin 61.7% vs 37.1%; non-GAAP gross margin 56.4% vs 29.1%.","Net loss $6.1M vs $24.9M prior year; near break-even cash flow; cash $329.5M.","Launched LucentAD blood test for Alzheimer's; positive Bio-Hermes study correlation with amyloid PET.","FY 2023 revenue outlook raised to $110-116M; cash burn lowered to $30-35M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013642","json":"https://secwatch.observer/filing/0001558370-23-013642.json","markdown":"https://secwatch.observer/filing/0001558370-23-013642.md","text":"https://secwatch.observer/filing/0001558370-23-013642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000155837023013642/0001558370-23-013642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000155837023013642/tmb-20230807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:09:03.206928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"068f6487b71bfb5e48ea52cf14d83bb2d3a588e4","claim":"Quanterix Corp reported second quarter ended June 30, 2023 results: revenue $31.0 million. Guidance raised.","evidence_excerpt":"today announced financial results for the three months ended June 30, 2023. Second Quarter Financial Highlights ● Total revenue was $31.0 million versus prior year second quarter total revenue of $23.5 million, an increase of 32%. Second quarter revenue also increased 9% sequentially driven by increased Accelerator Lab and consumables revenue. Second quarter revenue includes a one-time benefit of approximately $1.5 million related to product and license agreements. ● GAAP gross margin was 61.7% compared to prior year second quarter GAAP gross margin of 37.1%. Non-GAAP gross margin was 56.4% compared to prior year second quarter non-GAAP gross margin of 29.1%. ● Net loss was $6.1 million compared to prior year second quarter net loss of $24.9 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000155837023013642/0001558370-23-013642-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$31.0 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}